Halozyme Therapeutics, Inc. is a U.S.-based biopharmaceutical technology company focused on improving the delivery of injectable medicines. Its core ENHANZE drug delivery platform uses a proprietary recombinant human hyaluronidase (rHuPH20) to temporarily modify the subcutaneous space, enabling rapid, large‑volume subcutaneous administration of biologics that are often delivered intravenously.
Halozyme collaborates with global pharmaceutical companies to develop subcutaneous formulations across oncology, immunology, and other therapeutic areas, generating revenue through upfront payments, milestones, and royalties on partnered products. The company also supplies hyaluronidase-based products to support patient-friendly administration approaches. Halozyme is headquartered in San Diego, California.
None yet. When a new project in the record names Halozyme as owner, partner or investor, it shows here.
Independent Data Monitoring Committee advised stopping the trial for futility after an interim analysis; safety remained consistent and no new signals were seen.
Clinical, long-term and real‑world data show deeper ocular MG responses, one‑year efficacy in AChR‑Ab–negative MG, benefits of earlier treatment, CIDP durability and pipeline progress.
Modeling of MajesTEC‑3 trial data estimates a high cure fraction and nearly fourfold median OS benefit for teclistamab plus daratumumab FASPRO versus standard care in relapsed/refractory myeloma.
Final overall survival data for RYBREVANT plus chemotherapy in EGFR exon 20 insertions and tolerability updates for subcutaneous RYBREVANT FASPRO with prophylactic strategies.
Primary endpoint met in Phase 3 ALKIVIA: efgartigimod improved mean Total Improvement Score at Week 52 versus placebo; benefit emerged by Week 4 and was sustained across IMNM and DM.
OrigAMI-4 showed 42% response rate with >1/3 complete responses; FDA review shortened to ~6 months; drug targets EGFR and MET and is co-formulated with hyaluronidase.
CHMP recommendation follows MajesTEC-3 Phase 3 data showing HR 0.17 for PFS and HR 0.46 for OS at ~3 years in adults with RRMM after ≥1 prior therapy, with manageable safety.
ALKIVIA+ 52‑week data show sustained Total Improvement Score gains; RHO+ shows maintained response after switch to biweekly dosing; safety consistent across indications.
